MRC2 and neoplasm: By using an in vitro model to recapitulate the bone‐forming side of this complex setting, Endo180 was identified as a modulator of mineralized type I collagen deposition in primary human osteoblasts that is activated by the transforming growth factor‐β1 (TGFβ1) and TGFβ1 receptor (TGFβ1R) signalling axis and suppressed by paracrine signals from adjacent tumour cells 17.